NewAmsterdam Pharma Company N.V. Warrant

Company Profile

NewAmsterdam Pharma Company N.V. Warrant had its IPO on 2022-11-23 under the ticker symbol NAMSW.

The company operates in the Healthcare sector and Biotechnology industry. NewAmsterdam Pharma Company N.V. Warrant has a staff strength of 8 employees.

Stock update

Shares of NewAmsterdam Pharma Company N.V. Warrant opened at $1.9 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.8 - $2.01, and closed at $1.86.

This is a -7.01% slip from the previous day's closing price.

A total volume of 8,007 shares were traded at the close of the day’s session.

In the last one week, shares of NewAmsterdam Pharma Company N.V. Warrant have slipped by -0.01%.

NewAmsterdam Pharma Company N.V. Warrant's Key Ratios

NewAmsterdam Pharma Company N.V. Warrant has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months NewAmsterdam Pharma Company N.V. Warrant’s revenue was $93.50 million with a gross profit of $0 and an EBITDA of $33.78 million. The EBITDA ratio measures NewAmsterdam Pharma Company N.V. Warrant's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NewAmsterdam Pharma Company N.V. Warrant’s operating margin was 36.08% while its return on assets stood at 0% with a return of equity of 0%.

In Q4, NewAmsterdam Pharma Company N.V. Warrant’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

NewAmsterdam Pharma Company N.V. Warrant’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NewAmsterdam Pharma Company N.V. Warrant’s profitability.

NewAmsterdam Pharma Company N.V. Warrant stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

NewAmsterdam Pharma Company N.V. Warrant stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$471.10 million

Total Liabilities

$38.34 million

Operating Cash Flow

$0

Capital Expenditure

$15000

Dividend Payout Ratio

0%

NewAmsterdam Pharma Company N.V. Warrant ended 2024 with $471.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $471.10 million while shareholder equity stood at $422.26 million.

NewAmsterdam Pharma Company N.V. Warrant ended 2024 with $0 in deferred long-term liabilities, $38.34 million in other current liabilities, 608754000.00 in common stock, $-194463000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $383.50 million and cash and short-term investments were $383.50 million. The company’s total short-term debt was $64,000 while long-term debt stood at $0.

NewAmsterdam Pharma Company N.V. Warrant’s total current assets stands at $389.26 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.77 million compared to accounts payable of $20.85 million and inventory worth $0.

In 2024, NewAmsterdam Pharma Company N.V. Warrant's operating cash flow was $0 while its capital expenditure stood at $15000.

Comparatively, NewAmsterdam Pharma Company N.V. Warrant paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.86

52-Week High

$3.62

52-Week Low

$0.464

Analyst Target Price

$

NewAmsterdam Pharma Company N.V. Warrant stock is currently trading at $1.86 per share. It touched a 52-week high of $3.62 and a 52-week low of $3.62. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.97 and 200-day moving average was $1.76 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.